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Abstract 
Formal guidelines play an important role in disseminating the best available evidence 
knowledge and are expected to provide simple and practical recommendations for the most 
optimal management of patients with various conditions. Such guidelines have important 
implications for many disease states, which thereby could be more professionally managed in 
everyday clinical practice by clinicians with divergent educational backgrounds, and also more 
easily implemented in wards or outpatient clinics eliminating inequalities in health care 
management. 
In this brief Viewpoint, we provide an appraisal on the recommendations pertinent to the 
prevention of atrial fibrillation-related stroke or systemic thromboembolism, as provided in 
recently published guidelines for the management of this arrhythmia. 
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Introduction 
Prevention of stroke is central to the optimal management of patients with atrial fibrillation 
(AF). Oral anticoagulant therapy (OAC) using well-controlled vitamin K antagonists (VKAs) or 
non-VKA oral anticoagulants(NOACs) effectively reduces stroke and all-cause mortality in atrial 
fibrillation patients, but the treatment benefit must be balanced against the risk of OAC-related 
major bleeding. Worldwide, the VKAs remain the most widely used OAC, although the NOACs 
use is increasing rapidly
1
. 
Formal ATRIAL FIBRILLATION guidelines play an important role in disseminating the state-of-
the-art knowledge and are expected to provide simple practical guidance for atrial fibrillation 
management, which could be easily applied in clinical practice by clinicians with diverse 
educational backgrounds and various clinical commitments. Figure 1 provides an overview of 
several contemporary guideline treatment algorithms with recommendations for 
thromboprophylaxis in patients with atrial fibrillation
2
.  In 2014, guidelines from the 
AHA/ACC/HRS and National Institute for Health and Care Excellence (NICE) were published
3, 4
, 
while in 2016, a focussed update from the Canadian Cardiovascular Society (CCS)
5
 and new 
European Society of Cardiology (ESC) guidelines
6
 were published.  The last Asia-Pacific Heart 
Rhythm Society
7
 and American College of Chest Physicians (ACCP)
8
 guidelines on 
antithrombotic therapy in atrial fibrillation were published in 2012-2013, and new versions are 
pending. 
In this brief Viewpoint, we provide an appraisal of the recommendations pertinent to the 
prevention of atrial fibrillation -related stroke or systemic thromboembolism, as provided in 
more recently published guidelines for the management of patients with atrial fibrillation. 
 
Stroke and bleeding risk assessment  
Most of the contemporary international guidelines on atrial fibrillation management published 
since 2013 recommend the CHA2DS2-VASc score for stroke risk assessment in atrial fibrillation.  
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In line with the 2012 ESC Atrial Fibrillation Guidelines focused update
9
, the use of the CHA2DS2-
VASc score is a Class I, Level of evidence A recommendation in the new 2016 ESC Guidelines
6
.  
The CHA2DS2-VASc score, which has been validated in numerous different atrial fibrillation 
cohorts, provides a good balance of predictive ability and practicality and has often out-
performed other stroke risk assessment tools in the reliable identification of ‘truly low risk’ 
patients, who need no antithrombotic therapy due to low annual stroke rates of <1%
10, 11
. Like 
many clinical factor-based risk scores in the atrial fibrillation or non- atrial fibrillation setting, 
CHA2DS2-VASc only has a modest predictive value for identifying the ‘high risk’ patients who 
subsequently develop events.  As would be expected, for each point of the CHA2DS2-VASc score 
there would be a wide range of reported event rates, given that this would be dependent on 
population studied (trial vs ‘real-world’), clinical setting (hospitalised vs community cohorts), 
ethnicity, etc
12, 13
. 
The predictive value of clinical risk scores can always be improved by the addition of biomarkers 
(‘biological markers’, whether blood, urine or imaging based). In the light of recent sub-studies 
from the landmark NOAC trials (describing the role of various blood biomarkers in the 
prediction of stroke, bleeding or death in anticoagulated patients)
14-16
, the 2016 ESC Guidelines 
recommend that ‘biomarkers such as high-sensitive troponin or natriuretic peptide may be 
considered to further refine stroke and bleeding risk’ (Class IIb, Level B). This is a weak 
recommendation for a number of reasons. First, these findings were derived mostly from the 
already anticoagulated cohorts, and it is unclear whether they could be extrapolated to non-
anticoagulated patients, a substantially different population which includes many lower-risk 
patients for whom the decision to use an OAC is yet to be made. Second, a large body of 
evidence shows the association of various biomarkers of thrombogenesis, inflammation, 
myocardial damage, impaired cardiac function, oxidative stress, renal failure, etc. (e.g., von 
Willebrand factor, D-dimer, C-reactive protein, cardiac troponins, glomerular filtration rate, 
etc.) with increased risk of stroke in atrial fibrillation patients, and it is not clear why high-
sensitive troponin or natriuretic peptide should be preferred
17
. The particular biomarker cut-off 
values relevant for stroke or bleeding risk evaluation are unknown, notwithstanding the inter-
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assay variability in measuring the biomarker levels, cost issues and patient variability (some 
have a diurnal pattern and can be influenced by co-morbidities such as renal impairment).  
Many of these biomarkers not only predict stroke or bleeding, but death, myocardial infarction 
and heart failure – and may confuse clinicians who may try to balance the various outcomes.  
Finally, the use of biomarkers needs to be tempered by cost, as well as loss of simplicity and 
practicality for everyday use.  
The introduction of biomarkers to refine stroke risk stratification, albeit statistically improving 
on clinical scores, may result in delayed or postponed OAC initiation while waiting for test 
results with the risks inherent to the treatment omission. Nevertheless, the new 
recommendation to consider biomarkers for stroke and bleeding risk assessment indicates 
future development possibilities for improved risk prediction, especially for those at the 
‘borderline’ threshold for OAC. 
OAC-related bleeding risk 
The assessment of OAC-related bleeding risk is not a new concept but has been subject to 
considerable misuse and misinterpretation
18
. The 2016 ESC Guidelines provide guidance to 
practitioners, but focus on listing the modifiable, partly modifiable, non-modifiable and 
biomarker-related bleeding risk factors, rather than recommending a specific bleeding risk 
score, of which there are now many
19-23
, including the HAS-BLED score which was 
recommended in earlier ESC guidelines
9
 
19
. The modifiable bleeding risk factors, to which our 
attention is drawn are all factors listed in the HAS-BLED score.  
The HAS-BLED score
19
 has been well-validated in various atrial fibrillation cohorts, including 
patients treated with NOACs or a combination of OAC and antiplatelet drugs. The HAS-BLED 
score enables a simple identification of increased bleeding risk (i.e., score ≥3 points) and ‘flags 
up’ the patient potentially at risk of bleeding for more careful review and follow-up. 
Importantly, HAS-BLED draws attention to the reversible bleeding risk factors (summarised in 
Table 12 of the 2016 ESC guidelines) i.e. uncontrolled hypertension, labile International 
Normalized Ratio (INR), concomitant aspirin or non-steroidal anti-inflammatory drugs, excess 
alcohol, renal or liver function, or bleeding predisposition
24
.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
Several other bleeding risk scores are mostly less-well validated than HAS-BLED, and many 
would significantly under-perform in predicting VKA-related bleeding events by not considering 
the quality of anticoagulation control (i.e. labile INR) as a bleeding risk factor
25
. 
The reason for removing reference to a specific bleeding risk score and to focus on the 
modifiable bleeding risk factors in the 2016 ESC guidelines is related to the a misconception 
that specifying a particular bleeding risk score leads clinicians to use a high score value as a 
reason to withhold OAC
18
, which is an inappropriate use of bleeding scores. The use of a formal 
score should focus the physician’s attention towards provision of adequate education, 
management of modifiable risk factors, and perhaps implementation of modern adherence 
tools, such as electronic alerts, etc.
18
. The outline of bleeding risk factors in the new guidelines 
is very useful but could easily have been added to the more common bleeding risk assessment 
using the HAS-BLED score. Indeed, the new guidelines recommend that bleeding risk scores 
should be considered in atrial fibrillation patients on OAC to identify modifiable risk factors for 
major bleeding (Class IIa, Level B), but do not refer to a specific bleeding risk score, which may 
confuse clinicians.  
Nevertheless, we welcome the 2016 ESC Guidelines note that ‘a high bleeding risk score should 
generally not result in withholding OAC.’. This may be particularly important in atrial fibrillation 
patients with an acute coronary syndrome or percutaneous coronary intervention, in whom the 
choice of optimal treatment regimen (i.e., a combination of OAC and antiplatelet therapy for a 
variable time period) highly depends on the estimated thrombotic and bleeding risks.  
Bleeding management whilst on OAC is highlighted in the new ESC guidelines, especially since 
we are entering an era of reversal agents and specific antidotes to the NOACs, with 
idarucizumab already being available for dabigatran
26
.   
 
Stroke prevention strategies 
The new 2016 ESC Guidelines fully acknowledge that aspirin has no role in the prevention of 
atrial fibrillation-related stroke or systemic thromboembolism
27
 (Class III recommendation).  
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The 2012 ESC Guidelines focused update
9
 recommended a simple and effective stepwise 
approach to stroke prevention – first, identify patients at truly low risk of stroke who do not 
need any antithrombotic therapy (that is, males with CHA2DS2-VASc=0 and females with 
CHA2DS2-VASc=1) and next, consider OAC use in all other atrial fibrillation patients without 
absolute/strong contraindications to OAC (that is, in patients with a CHA2DS2-VASc score of ≥1, 
excluding female gender as the only risk factor). The new 2016 guidelines, however, re-
introduce the categorisation into the low, intermediate and high stroke risk strata.  
Whilst stating that male patients with a CHA2DS2-VASc score of 0 and female patients with a 
CHA2DS2-VASc score of 1 do not need any antithrombotic therapy and that patients at high risk 
of stroke (that is, male patients with a CHA2DS2-VASc score of ≥2 and female patients with a 
CHA2DS2-VASc score of ≥3) should be recommended OAC (Figure 1 and 2), the new ESC 
Guidelines increase the size of the ‘intermediate’ risk stratum of patients with a single CHA2DS2-
VASc risk factor (that is, with a CHA2DS2-VASc score of 1 [males] or 2 [females], Figure 2) and 
state that in such patients OAC ‘should be considered’ (Class IIa, Level B), cautioning that such 
approach should prevent the overtreatment (i.e., OAC overuse) in atrial fibrillation patients. 
However, the new ESC Guidelines do not provide explicit guidance how to ‘consider’ OAC use in 
the ‘intermediate’ stroke risk patients, and the approach with divergent CHA2DS2-VASc scores 
for males and females leads to gender-specific recommendation statements with an inherent 
risk for under-treatment of female patients.  
To inform decision-making pertinent to atrial fibrillation patients with a single additional stroke 
risk factor, the 2016 ESC Guideline Task Force commendably commissioned a systematic review 
of observational studies reporting the annual stroke rates in such non-anticoagulated 
patients
28
. The stroke rates in those studies were highly heterogeneous and sometimes low
10, 12, 
13, 29
.  A recent meta-analysis
30
 found that the annual stroke risk in the CHA2DS2-VASc score 1 
category is sufficiently high to prescribe a NOAC but not warfarin; however, the CHA2DS2-VASc 
score 1 data in the meta-analysis included low-risk females with score 1 who should not receive 
antithrombotic therapy, while the treatment threshold for well-managed warfarin with high-
quality anticoagulation control would probably approach that of NOACs
31
.  
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Older guidelines have previously given a strong recommendation for OAC for atrial fibrillation 
patients with 1 CHADS2 stroke risk factor
8
 (notably, CHADS2 and CHA2DS2VASc scores share 4 
stroke risk factors scoring 1 point).  There are no randomised trials specifically in patients with 
CHA2DS2-VASc 1; however, trials such as RELY, ARISTOTLE, SPORTIF (all of which compared 
NOACs vs warfarin), AVERROES and ACTIVE (both compared OAC to antiplatelet drugs) have all 
included patients with a single stroke risk factor resembling CHA2DS2-VASc score components, 
where subgroup analyses show evidence of benefit of NOAC vs warfarin
32, 33
, or OAC vs non-
anticoagulation
34, 35
.  An ancillary analysis from the SPORTIF trials showed that high time in 
therapeutic range (TTR) amongst warfarin users was associated with low event rates, 
suggesting that the treatment threshold for warfarin could be comparable to that seen for 
NOACs
31
. 
With a single stroke risk factor, it is only common sense that not all risk factors carry equal 
weight, and reported event rates would differ by study setting, population and ethnicity.  The 
most robust study (not considered by the guidelines)
10, 29
, larger than other European atrial 
fibrillation cohorts altogether (n=177,966), reported event rates according to the selected 
outcome criteria and specific CHA2DS2-VASc score levels
36
, showing how stroke rates vary with 
different methodological approaches, especially in patients with a single additional stroke risk 
factor. 
Methodological differences in the definition of cohorts ‘off OAC treatment’ would significantly 
influence the reported stroke rates, most relevant to a CHA2DS2-VASc score of 0 and 1. For 
example, two Swedish studies
37
 
38
 cited in the guidelines reported that patients with a CHA2DS2-
VASc score of 1 would not benefit from OAC, but these studies excluded all patients who during 
follow-up had initiated OAC treatment, thus ‘conditioning on the future’ and biasing outcomes 
towards lower event rates by excluding the higher-risk subjects who would have been started 
on OAC during follow-up.    
Simple stroke risk scores such as CHA2DS2-VASc are designed to be reductionist, and help 
dichotomise (and simplify) decision-making.  Thus, once the individual stroke risk has been 
established to be above the threshold for OAC use, what difference would it make if the score 
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was 2 or 9, or the patient’s risk was 2 or7% per year? OAC should be the default treatment at 
any stroke risk level exceeding the treatment threshold, excluding ‘truly low-risk’ AF patients 
(see the Birmingham ‘3-step’ algorithm, Figure 1).  
This simplified concept of considering OAC use in all atrial fibrillation patients with ≥1 additional 
stroke risk factors (excluding female sex as the only risk factor) leads to improved adherence to 
guidelines with better outcomes in daily practice and is cost-effective
4, 39
.  Modelling analyses 
show that adoption of the CHA2DS2-VASc-based approach and NOAC use would result in an 
annual reduction of >60000 strokes, deaths and bleeding events in Europe alone
40
.  
Hence, patients with atrial fibrillation and a single additional stroke risk factor should generally 
not be denied OAC on the grounds of a misperception that their risk of stroke is insufficiently 
high to justify OAC use. In comparison to no therapy or aspirin, the use of OAC (well-controlled 
VKA or NOACs) in such patients has been associated with a positive net clinical benefit, with 
significant reduction in stroke, systemic embolism or death and no increase in major bleeding 
relative to aspirin 
41, 42
. 
 
Choosing between NOACs and VKAs in daily practice 
Compared to VKAs, NOACs have the advantage of greater safety (significantly lower risk of 
haemorrhagic stroke or other intracranial haemorrhage, critical site or life-threatening/fatal 
bleeding) and more convenient use (fixed dosing without the need for routine laboratory 
control of anticoagulation intensity, but requiring strict adherence to treatment), and are at 
least as effective as VKAs in stroke prevention in atrial fibrillation patients.  
However, VKAs are still widely used for the prevention of atrial fibrillation -related stroke, 
mostly due to the cost and reimbursement issues, and for patients whose adherence to therapy 
is uncertain. The quality of the management of VKA therapy has generally improved, 
particularly in Europe. 
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The 2016 ESC Atrial Fibrillation Guidelines commendably prefer NOACs (dabigatran, 
rivaroxaban, apixaban or edoxaban) over VKAs when starting OAC in the NOAC-eligible patients 
(Class I, Level A), but do not make such a strong preference for NOACs in patients already taking 
VKA, even if the TTR is not well controlled or if the patient prefers NOACs in the absence of 
NOACs-specific contraindications (Figure 1 and 2) - the recommendation is only Class IIb, i.e 
may be switched. However, patients with poorly controlled INRs despite good adherence and 
compliance have a higher bleeding risk and should be (Class I recommendation) switched to a 
NOAC associated with a lower bleeding risk.  The preference to NOACs is a welcomed 
development, especially since the randomised trial data are clearly supported and augmented 
by large observational cohorts comparing various NOACs to warfarin, with evident consistency 
of effectiveness and safety
43
. 
The new guidelines do not provide a cut-off TTR value for the good quality of VKA 
anticoagulation, instead stating that TTR ‘should be kept as high as possible’ (Class I, Level A) 
and providing no formal guidance to clinicians how to assess the quality of the management of 
VKA therapy. 
The outcomes of VKA therapy strongly depend on the quality of anticoagulation, as measured 
by the individual patient’s TTR. Low TTR values (<65%) are associated with increased rates of 
stroke and major bleeding, and serious adverse events are particularly common during the 
inception period, in the first months of OAC use
44
.  Since the anticoagulation control in a VKA 
user can be influenced by a long list of clinical parameters, genetic testing before initiation of 
VKA therapy is not recommended (Class III). 
For those clinicians and patients who for any reason would prefer VKA as the initial OAC 
treatment, the SAMe-TT2R2 score provides a simple way to identify patients who would do well 
on VKAs in advance, avoiding potentially deleterious initial months of ‘trial of VKA treatment’. 
OAC-naive atrial fibrillation patients with a good TTR (SAMe-TT2R2 0-2) are likely to do well on 
VKAs,, whilst those with SAMe-TT2R2 >2 are less likely to achieve a good TTR and may instead 
be prescribed a NOAC
45
.  The SAMe-TT2R2 score has been validated in various atrial fibrillation 
cohorts and is predictive not only of the anticoagulation control quality with VKAs, but also of 
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all-cause mortality or a composite endpoint of thromboembolic events, major bleeding and 
mortality
46
.  The SAMe-TT2R2 is easily calculated assigning 1 point each to female sex, age of 
<60 years, history of ≥2 co-morbidities  or treatment with drugs interacting with VKAs (e.g., 
amiodarone) and 2 points each to tobacco use and non-Caucasian ethnicity. Although the 2016 
ESC guidelines briefly mention the SAMe-TT2R2 score, there is no formal recommendation on its 
use, because the score has not been tested in randomised trials. 
The 2016 ESC guidelines recommend (Class IIa) a specific NOAC in preference to other NOACs 
for patients at increased risk for gastrointestinal bleeding. Such recommendation is based on 
the randomised trials, post-market studies and meta-analysis, although the head-to-head 
comparisons between the NOACs are lacking. The recommendation may also imply that the 
lower doses of rivaroxaban, edoxaban or dabigatran could be preferred for these patients. 
However, little information is available about the efficacy of rivaroxaban 15mg once daily
47
, and 
the low dose regimen of edoxaban was less efficacious than warfarin
48
. Divergent results from 
the various trials emphasise the different patient populations as reflected by different bleeding 
rates in their VKA arms, different CHA2DS2-VASc scores, variable definitions of major bleeds 
etc., all of which could have influenced the results, and makes head-to-head comparisons 
questionable.   
 
Specific considerations 
The 2016 ESC guidelines have comprehensive sections on the optimal management of atrial 
fibrillation patients presenting with an acute stroke or intracranial haemorrhage (reflecting the 
collaboration with the European Association for Cardiothoracic Surgery and the European 
Stroke Association) or patients with an acute coronary syndrome or percutaneous coronary 
intervention/stenting (with recommendations broadly consistent with the recent European 
consensus document
49
). Clearly, complex atrial fibrillation patients need a multidisciplinary 
approach and carefully integrated care, which is a welcomed new recommendation (Class IIa) 
made in the guidelines
41, 42, 50
. 
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Patient education and their values and preferences are an increasingly important feature in the 
guidelines
51
. This is relevant since OAC discontinuation (affecting 20-50% of patients in the first 
year of OAC treatment) is an important problem. The 2016 ESC guidelines provide important 
novel guidance in this emerging field.  
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Figure 1. An overview of guideline algorithms for thromboprophylaxis in patients with atrial 
fibrillation (adapted from Lip et al 
2
) 
 
 
 
ESC: European Society of Cardiology; AHA/ACC/HRS: American Heart Association/ American 
College of Cardiology/Heart Rhythm Society; CCS: Canadian Cardiology Society; VKA: Vitamin 
K antagonist; OAC: Oral Anticoagulant; NOAC: Non-VKA Oral Anticoagulant; ASA: Acetyl-
Salicylic-Acid; CAD: Coronary Artery Disease; TTR: Time in Therapeutic Range; INR: 
International Normalized Ratio.  
  
Mechanical heart valves (1-4); Moderate or severe 
mitral stenosis (1,3,4); Bioprosthetic heart valves (2) 
VKAYes
CHA2DS2-VASc CHADS65
0 1* ≥2
No
STROKE RISK ASSESSMENT
No antithrombotic 
treatment
ASA
OAC
Age ≥65y and/or 
CHADS2 risk factors 
No
CAD or arterial 
vascular disease
No
NOAC VKA
Yes
Step 1 
Identify low-risk 
patients
CHA2DS2-VASc = 0 (males)
or  CHA2DS2-VASc = 1 
(females)*
Step 3 
Decide between NOAC 
or VKA with high TTR 
SAMe-TT2R2 score >2
SAMe-TT2R2 score 0-2 VKA
NOAC or 
VKA with regular 
review, education 
and INR checks
§Also calculate the HAS-BLED score;
If ≥3, address the modifiable bleeding risk factors and plan regular review and follow-up.
1. 2016 ESC
2. 2014 AHA/ACC/HRS
3. 2016 CCS
4. Birmingham 3-step algorithm
*Female sex without additional stroke risk factors does not merit OAC.
Calculate
SAMe-TT2R2
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Step 2 
Use OAC in all patients 
with ≥1 CHA2DS2-VASc 
stroke§ risk factors*
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Figure 2. The 2016 European Society of Cardiology Guideline Recommendation on 
thromboprophylaxis in atrial fibrillation (adapted from the original document).  
 
AF: Atrial Fibrillation; OAC: Oral Anticoagulant Therapy; AP: Antiplatelet Drugs; LAAO: Left 
Atrial Appendage Occlusion; NOAC: Non-vitamin K Oral Anticoagulant; VKA: Vitamin K 
Antagonist. 
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CLINICAL SIGNIFICANCE 
 
 
• Formal guidelines play an important role in disseminating the state-of-the-art 
knowledge and are expected to provide simple practical guidance for atrial 
fibrillation management, which could be easily applied in clinical practice by 
clinicians with diverse educational backgrounds and various clinical 
commitments.   
• We provide an appraisal on the recommendations pertinent to the 
prevention of atrial fibrillation-related stroke or systemic thromboembolism, 
as provided in recently published guidelines for the management of this 
arrhythmia. 
 
  
 
